Merck & Co., Inc. (NYSE:MRK) just can’t get enough of its stock. And the pharma wants it now.
The company announced Tuesday after the close that it had set up an accelerated share repurchase agreement with Goldman Sachs Group, Inc. (NYSE:GS) to buy $5 billion worth of Merck stock. The agreement calls for Goldman Sachs to deliver 99.5 million Merck shares at current market prices — about $4.7 billion at current prices — with the rest based in a weighted average of the price of Merck stock during the program that’s scheduled to end no later than Nov. 25.
Through April, Merck & Co., Inc. (NYSE:MRK) repurchased $772 million worth of Merck stock this year. The purchases are part of a $15 billion stock repurchase that Merck announced earlier this month and the remaining part of a $5 billion stock program from 2011.
Merck actually borrowed money to finance the repurchase. It’s not like it couldn’t afford to make the purchase with cash on hand; at the end of the first quarter Merck had a nest egg of $13 billion. But much of that cash is likely overseas.
Is Merck stock really cheap?
Merck & Co., Inc. (NYSE:MRK) is guiding for adjusted EPS between $3.45 and $3.55. At the midpoint, its P/E is 13.5. If you flip that number over — earnings divided by price — you get the earnings ratio of 7.4%, meaning that essentially every dollar Merck spends buying back shares yields 7.4% because it removes shares from the EPS equation.
The company also doesn’t have to pay the dividend — currently 3.7% — on Merck stock that it buys, so that increases the return on the repurchases.
The bonds that Merck & Co., Inc. (NYSE:MRK) sold to pay for the buyback carry interest rates between 0.7% and 4.15%. There are notes due in 2016 and 2018 that have a floating interest rate, but it seems safe to assume that they’re less than 4% at this point.
The buybacks certainly looks like a good move for Merck. It can use the money it would have spent on dividends to pay the interest on the bonds and increase its EPS in the process. That should, in theory, increase its value.
The buybacks are a good move, but they might not be the best use of Merck & Co., Inc. (NYSE:MRK)’s cash. It’s possible that Merck could get a higher return by buying other companies to boost EPS by increasing earnings rather decreasing share count. As it struggles with falling revenue from generic competition, Merck stock could use a boost.
Amarin Corporation plc (ADR) (NASDAQ:AMRN) would be a good fit with its lipid-lowering drug, Vascepa. Merck sells cholesterol-lowering Zetia and combo products, so the overhead to market an additional cardiovascular drug would be pretty minimal. Amarin Corporation plc (ADR) (NASDAQ:AMRN) is looks cheap at $1 billion, although the strength of its patents is a potential issue and may be the reason why no one has bought the company yet.